Gland Pharma gets USFDA’s approval for Zoledronic Acid Injection

06 Feb 2026 Evaluate

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) Single-Dose Bags.

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/ mL) of InfoRLife. This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors. According to IQVIA, the product had US sales of approximately $6.7 million for the twelve months ending November 2025. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1821.00 -15.25 (-0.83%)
20-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.45
Dr. Reddys Lab 1280.30
Cipla 1341.45
Zydus Lifesciences 901.00
Lupin 2219.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×